PAIN THERAPEUTICS CONFERENCE
Pain Therapeutics aims to explore areas such as the use of molecular targets for pain drug discovery, identification of novel analgesics, developments in narcotic drugs, results from transgenic animals and the market position for pain therapeutics.
(PRWEB) May 21, 2002
PAIN THERAPEUTICS CONFERENCE
10th & 11th JUNE 2002, THE HATTON, LONDON
Http://www. smi-online. co. uk/painthera8.asp (http://www. smi-online. co. uk/painthera8.asp)
The following is an overview for the Pain Therapeutics event. Critical
Issues in Pain Trials for the Elderly, 12th June 2002, is a one day
Interactive forum in association with Quintiles. SMi is also hosting a
Half-day interactive forum Clinical Quantitative Sensory Testing, 12th
June 2002, in association with Imperial College, Hammersmith Hospital, RDG
Medical and Perimed
Pain Therapeutics aims to explore areas such as the use of molecular
Targets for pain drug discovery, identification of novel analgesics,
Developments in narcotic drugs, results from transgenic animals and the
Market position for pain therapeutics.
The conference has been organised specifically to bring together leading
Senior executives with focused and timely information. I am sure you will
Agree the event will keep you abreast of all the latest developments in
Asthma therapeutics.
DON'T MISS A ONE DAY INTERACTIVE EXECUTIVE BRIEFING
Critical Issues in Pain Trials for the Elderly
12th June 2002
The Hatton, London
DON'T MISS A HALF DAY INTERACTIVE EXECUTIVE BRIEFING
Clinical Quantitative Sensory Testing
12th June 2002
The Hatton, London
Have a scroll down, and see what you DON'T want to miss out on!
A unique opportunity to learn from leading industry experts including:
Dr Mark Field, Senior Principal Scientist, Pfizer
Dr Peter McIntyre, Laboratory Head & Programme Team Head, Novartis
Dr Steven England, Principal Scientist, Pfizer
Dr Andy Dray, Scientific Director, AstraZeneca
Dr Zahid Ali, Senior Research Pharmacologist, Merck Sharpe & Dohme
Dr Robert Medve, Senior Director, Johnson & Johnson
Dr David Ellis, Medical Director, Elan
Dr Jenny Longmore, Pain, Migraine Research, Merck Sharpe & Dohme
Dr Tony Priestley, Associate Director, Schering Plough
Dr James Sullivan, Divisional Vice President, Neuroscience, Abbott
Benefits of attending:
Keep up to date with the very latest developments in pain therapeutics
Find out about the advances in treating different types of pain
Learn about the novel drug discoveries and drug deliveries
Take advantage of the networking opportunities
Meet the key decision makers
Establish the future prospects for pain research
CONFERENCE AGENDA
"SMi conferences - very good speakers and topics, excellent for
Networking" SMi evaluation form
SMI'S THIRD ANNUAL
PAIN THERAPEUTICS
10th & 11th JUNE 2002, THE HATTON, LONDON
Day One - 10th June 2002
8.30 Registration & Coffee
9.00 Chairman's Opening Remarks
Dr Guy Seabrook, Project Director, Merck Sharpe & Dohme
INTRODUCTION TO PAIN
9.10 Overview of opportunities in pain therapeutics
· Market opportunity
· Issues with existing therapies
· Unmet medical need
· Key factors for success of new compounds
· Major obstacles to success
Dr Steven England, Principal Scientist, Pfizer
PAIN MANAGEMENT
9.40 Therapies, drug delivery and analgesics
· Epidemiology and market segmentation
· Current treatments for chronic pain
· Emerging therapies
· The role of drug delivery technology in pain management
· The search for new analgesics
Dr Phillip Birch, Chief Scientific Officer, Ionix Pharmaceuticals
CURRENT RESEARCH IN PAIN THERAPEUTICS
10.20 Recent research developments in pain therapy research
· Molecular targets in pain research
· Research methodologies
· Tools for pain research
· Current pain drugs and therapeutic modalities
· New targets for pain relief ligands
Dr Zahid Ali, Senior Research Pharmacologist, Merck Sharpe & Dohme
11.00 Morning Coffee
MANAGING PAIN
11.20 Approaches to managing pain
· New approaches to improve pain management
· Treatments for chronic pain
· Different types of treating pain
· Different types of drug delivery in pain management
· Future pain management techniques
Dr Barbara Schneider, Director, Clinical Development, Kendle
DEVELOPMENTS
12.00 New developments in narcotic drugs
· Traditional opiates
· New developments
· M6G
· Pain relief
· Current trends and research
· Future pain management techniques
Dr Terry Smith, Development Director, CeNeS
12.40 Networking Lunch
PAEDIATRIC PAIN
2.00 Changing the paradigm
· Historical context
· Current challenges
· Defining the population
· Research methods
· Ethical principles
· The way forward
Dr Robert Medve, Senior Director, Johnson & Johnson
NEUROPATHIC PAIN
2.40 Understanding neuropathic pain
· What is neuropathic pain
· How does neuropathic pain differ from other types of pain
· Current treatments for neuropathic pain
· Preclinical models of neuropathic pain - assessment of pain subtypes
· Future opportunities
Dr Mark Field, Senior Principal Scientist, Pfizer
3.20 Afternoon Tea
CHRONIC PAIN
3.40 Chronic pain and its treatment
· Common chronic pain syndromes
· Preclinical animal models
· Current pharmacotherapeutic
· Efficacy vs. tolerability
· New therapeutic approaches and future opportunities
Dr Tony Priestley, Associate Director, Schering Plough
NEUROPATHIC PAIN
4.20 New discoveries for neuropathic pain
· Development of unique, pain controlling therapies
· An understanding of how neuropathic pain differs from other types of pain
· Understanding the underlying mechanisms of neuropathic pain
· New molecular approaches to the treatment of neuropathic pain
· Different kinds of treatment
· New and emerging trends
Dr James Sullivan, Divisional Vice President, Neuroscience, Abbott
5.00 Chairman's Closing Remarks and Close of Day One
Day Two - 11th June 2002
8.30 Re-registration & Coffee
9.00 Chairman's Opening Remarks
Dr Najib Babul, Director, Pain, TheraQuest
MIGRAINE PAIN
9.10 New discoveries for migraine pain
· Development of unique, pain controlling therapies
· An understanding of how neuropathic pain differs from other types of pain
· Understanding the underlying mechanisms of migraine pain
· Different kinds of treatment
· New and emerging trends
Dr Jenny Longmore, Pain, Migraine Research, Merck Sharpe & Dohme
ANALGESIA STRATEGIES
9.40 Treating pain symptoms and disease
· Overview mechanisms of acute and chronic pain
· Pain as disease what are the causes and pathophysiological substrates?
· What are the best target families for novel analgesia approaches?
· Focus on G protein coupled receptors: why?
· Some current initiatives: opioids receptors, cannabinoid receptors,
Sensory neurone specific receptors.
Dr Andy Dray, Scientific Director, AstraZeneca
FIBROMYALGIA SYNDROME
10.20 FMS as a target for novel analgesic drugs
· Definition of FMS
· Neurophysiological basis of fibromyalgia pain
· Assessment of fibromyalgia pain
· Current therapies
· Clinical studies
· Potential future drug therapies
Dr Graham Birrell, Business Development Manager, Intercern
11.00 Morning Coffee
OPIOID ANALGESIA
11.20 Improving opioid analgesia
· Central delivery using peptrans vectors
· Rapid and extended analgesia
· No respiratory depression
· Effective in inflammatory models
· Attractive pharmacodynamic profile
Prof. Tony Rees, Director, Science, Synt:em
VANILLOID RECEPTORS AND NOCICEPTION
12.00 The role of vanilloid receptors in nociception
· Expression of vanilloid receptors
· Function of cloned VR1
· Comparison of VR1 receptors from different species
· VR1 as a pivotal transducer
· Related receptors
Dr Peter McIntyre, Laboratory Head & Programme Team Head, Novartis
12.40 Networking Lunch
THE DEVELOPMENT OF INTRATHECAL ANALGESICS IN REFRACTORY PAIN
1.40 Ziconotide, a new peptide intrathecal analgesic
· Overview of intrathecal analgesia
· Summary of ziconotide pharmacology
· Challenges in the design of intrathecal trials
· Patients with refractory pain
· Analgesic efficacy of ziconotide
· Safety profile of intrathecal ziconotide
Dr David Ellis, Medical Director, Elan
ANALGESIC DRUG DEVELOPMENT IN THE MULTIDOSE AND CHRONIC PAIN SETTING
2.20 Emerging issues and potential solutions
· Current challenges with multidose evaluation in acute pain
· Solutions for multidose analgesic evaluation in acute pain
· Selection of chronic pain models for pain studies
· Endpoint selection in chronic pain
· Key study design consideration in chronic pain
· Future opportunities
Dr Najib Babul, Chief Executive Officer, TheraQuest
MOLECULAR TARGETS
3.00 Molecular targets in human pain states
· Distribution of key ion channels, receptors, neuroeffectors
· Inducible enzymes and their products
· Human tissue studies in common pain states
· How do animal models relate to human data?
· How can we increase success of Phase II clinical trials?
Prof. Praveen Anand, Professor, Clinical Neurology & Head, Peripheral
Neuropathy Unit, Imperial College of Science, Technology & Medicine,
Hammersmith Hospital
3.40 Afternoon Tea
NOVEL DRUG DISCOVERIES
4.00 Novel measures in analgesia
· Opioid-sparing
· Tolerance
· Neuropathic pain qualities
Novel drug delivery in neuropathic pain
· Targeted peripheral analgesia
Dr Bradley Galer, Vice President, Scientific Affairs, Endo Pharmaceuticals
NEUROPATHIC PAIN
4.30 Overview of current treatments and examination of the short and long
Term future of this market of opportunity
· Current market overview
· Pipeline analysis
· The Pfizer factor: neurontin and pregablin
· Potential impact of anticonvulsant trial failures
· Improving the analgesia: the short term future of the market
· Treating the underlying cause: the long term goal
Dr Susanne Begley, Head, Central Nervous System, Datamonitor
5.00 Chairman's Closing Remarks and Close of Conference
One Day Executive Briefing:
Critical Issues in Pain Trials for the Elderly
12th June 2002, The Hatton
[In association with: Ingenium]
9.00am - 5.30pm
Workshop Leader - Mason W. Diamond, Sr. Vice President, Business
Development, Ingenium Research
The treatment of pain in older adults is an enormous undertaking; the
Numbers older adults affected with pain is overwhelming. In many cases the
Pain is manageable with drugs or other treatments, yet each year millions
Of older people are forced to endure unrelieved suffering. The problem is
Further complicated by the cognitive and emotional difficulties
Encountered in this population. Unique pharmacodynamic and pharmacokinetic
Issues complicate pain management in older adults. Even though this
Population encompasses the largest number of pain sufferers and
Purchasers of analgesic products, it remains in greatest need of
Innovative therapies. Hopefully, the future will see an increase in
Clinical trials dealing specifically with this age group.
This workshop will deal with the following topics of interest to those who
Work with older patients in clinical trials focused on pain therapeutics
Epidemiology of pain in older adult populations
Pharmacodynamics and pharmacokinetics of pain treatments unique to older
Adults
Quality of life issues in older adults with pain
Assessing the challenges of measuring pain in older adults
Ethical issues in working with vulnerable elderly populations
Recruitment strategies in older populations
Market implications
Visions for the future of pain relief in the aged
About Ingenium
Ingenium is a contract research organization providing a broad range of
Global services to the Biotech, Pharmaceutical and Medical Device
Industries. Among these services, Ingenium offers program management,
Data management, and statistical, regulatory, therapeutic and strategic
Consulting. Ingenium is an innovative company, with a strong commitment
To meeting the ever-changing needs of Healthcare Product Development.
About your briefing leader:
Dr. Diamond is the Senior Vice President for Business Development and a
Senior Scientific Consultant for Ingenium Research, Inc. He has over 15
Years of clinical, academic, and industry experience in pain management
And the development of new pain therapies. Dr. Diamond has taught pain
Management while on the faculty of New York University College of
Dentistry and at the Mt. Sinai Hospital in New York City.
Dr. Diamond has held clinical, regulatory and project management positions
At Pharmaceutical, Biotech and Contract Research companies, including
American Home Products and Purdue Pharma. He has designed and conducted
Clinical trials employing numerous pain models, including cancer, chronic
Back pain, orthopaedics, arthroscopy, arthritis, dental, and actual-use.
In addition, Dr. Diamond has interacted extensively with the U. S. FDA both
On product development and on workshops for the Non-prescription Drug
Manufacturers Association (now the Consumer Healthcare Product
Association).
Half Day Executive Briefing:
Clinical Quantitative Sensory Testing
12th June 2002, The Hatton
[In association with: Imperial College, Hammersmith Hospital; RDG Medical;
Perimed]
Synopsis of Briefing
Clinical neurophysiological studies are important in the detection of
Nerve injury or disease, and hypersensitivity associated with pain states.
They often also provide insight into underlying structural and functional
Mechanisms, and end-points for clinical trials. Quantitative sensory and
Autonomic testing may provide information about small myelinated and
Unmyelinated nerve fibres, as well as large fibre function. These tests
Can be particularly useful in patients with mechanical or thermal
Hypoalgesia, hyperalgesia and allodynia, particularly when other
Investigations are unhelpful, by providing objective assessment of
Abnormalities within and outside the territory of the affected nerve /
Tissue, and by establishing selective involvement of small nerve fibres.
Quantitative sensory testing (QST) is also useful for epidemiological and
Therapeutic studies. In this workshop, the theory and practice of QST in
The clinic will be addressed, with hands-on experience for the delegates.
Time table of the Briefing
9.00am - 12.30 pm
Chairman: Professor P Anand, Imperial College, Hammersmith Hospital,
London, UK
Faculty: Mr Rod Gemmell, RDG Medical, Croydon, Surrey, UK
Mr Phillip Basham, Perimed, Bury St Edmunds, Suffolk, UK
Thermal, vibration, touch thresholds (Rod Gemmell, RDG Medical)
Demonstration of sensory testing (with Medoc Neurosensory Analyzer
Equipment) including the use of thermal stimulus for quantifying warm and
Cool thermal thresholds and hot and cold pain thresholds (A delta and C
Fibres), vibration stimulus for the assessment of vibration perception
Thresholds (A alpha / beta fibres), and von Frey monofilaments for
Assessing touch sensitivity. Delegates will be able to experience the
Sensations for themselves.
Skin sensory axon-reflexes, and micro-pharmacology with iontophoresis
(Phil Basham, Perimed)
Skin axon-reflex vasodilatation is a useful measure of nociceptor
Function, which does not require attention or voluntary responses from the
Patient. This may be elicited by agents such as histamine and capsaicin,
And measured by laser Doppler fluxmetry: these procedures will be
Demonstrated with the following equipment. The PeriIont
Micro-pharmacology System is a useful tool for drug delivery by
Iontophoresis in the investigation of microcirculatory neuro-vascular
Responses. Periflux SYSTEM 5000 is a multi-mode instrument that not only
Includes modules for Laser Doppler Perfusion measurement, but also for
Transcutaneous Oxygen and Carbon Dioxide (TcpO2/pCO2). The PeriScan PIM
II Laser Doppler Imager produces two-dimensional images of the perfusion
Distribution over an area of tissue.
About your briefing leader:
Professor Praveen Anand is Professor of Clinical Neurology and Head of the
Peripheral Neuropathy Unit at the Hammersmith Hospital, London. He trained
In medicine at the universities of Oxford and Cambridge, and in medicine
And neurology at the Royal Post-gradual Medical School, Hammersmith
Hospital, and the National Hospital for Neurology and Neurosurgery, Queens
Square, London.
He focuses his research on pathophysiological and molecular sensory
Mechanisms in human neuropathies, including diabetic, traumatic, leprosy,
And genetic neuropathies. The aim of his unit is to bridge the gap between
Pre-clinical discoveries and their successful application in Phase II
Clinical trials.
Previous SMi Pharmaceutical Conference Attendees
Abbott Laboratories
Allergan
Amersham
Amgen
AstraZeneca
Aventis
Bayer
Biogen
Boehringer Ingelheim
Bristol-Myers Squibb
Daiichi Pharmaceuticals
Dupont Pharmaceuticals
Elan
Eli Lilly
F. Hoffmann - La Roche
Genentech
Genzyme
Johnson & Johnson
Merck & Co
Merck KgaA
Novartis
Novo Nordisk
Pfizer
Pharmacia
Procter & Gamble
Sanofi-Synthelabo
Schering AG
Schering-Plough
Serono
Yamanouchi
SPONSORSHIP AND EXHIBITION OPPORTUNITIES:
SMi offer sponsorship, exhibition, advertising and branding packages,
Uniquely tailored to complement your company's marketing strategy. Prime
Networking opportunities exist to entertain, enhance and expand your
Client base within the context of an independent discussion specific to
Your industry. Should you wish to join the increasing number of companies
Benefiting from sponsoring our conferences please call Jackie McDonald,
SMi Sponsorship on tel +44 (0) 20 7827 6710 or jmcdonald@smi-online. co. uk
EXECUTIVE PACKAGES
Option A Conference & Executive Briefing 1 Fee: £1698.00 VAT: £297.15
Total: £1995.15
Option B Conference & Executive Briefing 2 Fee: £1498.00 VAT: £262.15
Total: £1760.15
Option C Conference only Fee: £1099.00 VAT: £192.33 Total: £1291.33
Option D Executive Briefing 1 only (full day) Fee: £699.00 VAT: £122.33
Total: £821.33
Option E Executive Briefing 2 only (half day) Fee: £499.00 VAT: £87.33
Total: £586.33
ACADEMIC DISCOUNT
Option F Conference only Fee: £549.00 VAT: £96.15 Total: £645.66
Option G Conference & Executive Briefing 1 Fee: £1148.50 VAT: £200.98
Total: £1349.48
Option H Conference & Executive Briefing 2 Fee: £948.50 VAT: £165.99
Total: £1114.49
Academic Researchers will receive 50% discount on marked price. Proof of
Status to be sent with registration.
SO HOW DO YOU REGISTER FOR THIS EVENT?
· Places are strictly limited. Register today to guarantee your place at
This event.
· Register on our secure website at our
Http://www. smi-online. co. uk/painthera8.asp (http://www. smi-online. co. uk/painthera8.asp) quoting reference G58 4WK EM
· Register online and receive full information on all of SMi's
Pharmaceutical conferences
· Or call James Kennedy on tel +44 (0) 207 827 6186, or email at
Jkennedy@smi-online. co. uk quoting reference G58 4WK EM
